



Lumizyme[®] (alglucosidase alfa)
**BILLING AND CODING GUIDE
FOR REIMBURSEMENT**

USING THIS BILLING AND CODING GUIDE

Notice: This guide is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician’s independent diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change.

The coding information discussed in this guide may be used to communicate services rendered when filing claims for Lumizyme.

- These codes are being provided for informational purposes only and should be verified, as codes may change
- The provision of billing codes does not constitute reimbursement or legal advice
- Providers are solely responsible for ensuring the accuracy of billing submissions to any payer

The codes listed herein may not apply to all patients or to all health plans. Conversely, additional codes not listed in this guide may apply to some patients. In addition, be aware that codes may change over time.

Sanofi is committed to working with providers, as well as with public and private payers, to help ensure access to Lumizyme as indicated. If you still have questions after reviewing this guide, please contact **CareConnectPSS®** at **1-800-745-4447**, Option 3. Sanofi’s **CareConnectPSS Case Managers** have expertise in reimbursement, insurance, case management, and the healthcare delivery system and can provide information to physicians and their patients about the reimbursement process.



TABLE OF CONTENTS

Indication and Important Safety Information	3
Coding Summary	5
Sample Reimbursement Forms	8
Additional Billing and Coding Considerations	10
Dosing Information	12
Patient Support Services	13
Ordering Information for Lumizyme	14

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency).

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, IMMUNE-MEDIATED REACTIONS, AND RISK OF ACUTE CARDIORESPIRATORY FAILURE

Hypersensitivity Reactions Including Anaphylaxis

Patients treated with LUMIZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during LUMIZYME administration. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue LUMIZYME immediately and initiate appropriate medical treatment.

Consider risks and benefits of re-administering LUMIZYME following severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily stopped. Prior to LUMIZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids.

Immune-Mediated Reactions

Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following LUMIZYME treatment. Monitor patients for the development of systemic immune-mediated reactions involving skin and other organs while receiving LUMIZYME.

Risk of Acute Cardiorespiratory Failure

Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload and require additional monitoring.

Infusion Associated Reactions (IARs): Infusion Associated Reactions (IARs) have been observed in patients treated with Lumizyme. Discontinue immediately or adjust the infusion rate and provide medical treatment based on the severity of the reaction. Closely monitor patients who have experienced IARs when re-administering LUMIZYME.

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for LUMIZYME infusion.

Risk of Antibody Development: Patients with Infantile-onset Pompe disease should have a cross-reactive immunologic material (CRIM) assessment early in their disease course and be managed by a specialist knowledgeable in immune tolerance induction in Pompe disease to optimize treatment. Evidence suggests that patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy.

IMPORTANT SAFETY INFORMATION (cont'd)

Monitoring: Laboratory Tests: Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter. Patients who experience hypersensitivity reactions, including anaphylaxis, may also be tested for IgE antibodies to LUMIZYME and other mediators of anaphylaxis.

ADVERSE REACTIONS

The most frequently reported adverse reactions ($\geq 5\%$) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.

Please see [Full Prescribing Information](#) for complete details, including **Boxed WARNING**.

CODING SUMMARY

Diagnosis Code

Codes used to formalize diagnosis come from the *International Classification of Diseases, Tenth Revision*, which was originally developed by the World Health Organization.¹ The *ICD-10-CM* diagnosis code for Pompe disease, to be used in conjunction with the administration of Lumizyme, is E74.02.² Lumizyme treats both late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD), and E74.02 may be used to document either diagnosis.³

ICD-10-CM CODES²	
E00-E89	Endocrine, nutritional, and metabolic diseases
> E74	Other disorders of carbohydrate metabolism
>> E74.02	Pompe disease

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

National Drug Code (NDC)

National Drug Codes are unique 3-segment numbers that serve as a universal product identifier for human drugs in the US.⁴ Lumizyme has 10-digit NDCs displayed on its packaging. In most cases, these codes should be converted to 11-digit NDCs for billing purposes.⁵ The table below shows the 10-digit and 11-digit NDCs for single-vial and 10-vial cartons of Lumizyme.



NOTE: Payer requirements for NDC use and format may vary. Please contact each payer for specific coding policies.

10-DIGIT NDC	
58468-0160-1	Carton of 1 single-dose vial
58468-0160-2	Carton of 10 single-dose vials
11-DIGIT NDC	
58468-0160-01	Carton of 1 single-dose vial
58468-0160-02	Carton of 10 single-dose vials
How supplied	Lumizyme is supplied as a sterile, nonpyrogenic, white to off-white lyophilized cake or powder, in single-dose vials, for intravenous use after reconstitution and dilution. Each vial contains 10.5 mL reconstituted solution and a total extractable volume of 10 mL at 5 mg/mL alglucosidase alfa. ³

IMPORTANT SAFETY INFORMATION

Infusion Associated Reactions (IARs): Infusion Associated Reactions (IARs) have been observed in patients treated with Lumizyme. Discontinue immediately or adjust the infusion rate and provide medical treatment based on the severity of the reaction. Closely monitor patients who have experienced IARs when re-administering LUMIZYME.

Please see Important Safety Information on pages 3-4 and [Full Prescribing Information](#) for complete details, including **Boxed WARNING**.



Lumizyme[®]
(alglucosidase alfa)

CPT® Code

CPT codes are used to describe the procedures performed on a patient and/or how a drug or supply being billed was administered.⁶ The CPT codes most commonly associated with the administration of IV-infused biologic therapies like Lumizyme are listed below. Whenever possible, confirm the preferred coding policy with payers prior to administration of Lumizyme.

PRIMARY CODES ⁷	
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Each additional hour (list separately in addition to code for primary procedure; report 96366 for infusion intervals of greater than 30 minutes beyond 1-hour increments)*

*Per CMS guidelines, if the incremental amount of infusion time is 30 minutes or less, the time is not to be billed separately. Note that some payers may require including on the claim the actual number of minutes of infusion time.

CMS, Centers for Medicare & Medicaid Services; CPT®, Current Procedural Terminology; IV, intravenous.

CPT® is a registered trademark of the American Medical Association, 2022.

HCPCS Procedure Code

HCPCS codes are assigned by CMS and are used by Medicare and most private payers to describe products administered in a physician’s office or hospital setting.⁸ Note that the coding system is not a methodology for making coverage or payment determinations. The existence of a HCPCS code does not imply coverage; it implies only that the product may be reimbursed if covered.

PERMANENT J CODE ⁹	Description
J0221	Injection, alglucosidase alfa (Lumizyme), 10 mg

HCPCS, Healthcare Common Procedure Coding System.

IMPORTANT SAFETY INFORMATION (cont’d)

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for LUMIZYME infusion.

JW modifier: Medicare and some commercial payers require providers and suppliers to report the JW modifier on Part B drug claims for discarded drugs and biologics.¹⁰ Refer to each payer's policy for coding and documentation requirements.

Place of Service Codes

Because Lumizyme can be administered in various settings (infusion center, physician office, patient's home if deemed clinically appropriate by the prescribing physician), it is important to populate a claim with the appropriate 2-digit Place of Service (POS) code.¹¹ Always verify the preferred POS codes for your patient's health plan before submitting a claim.

IMPORTANT SAFETY INFORMATION (cont'd)

Risk of Antibody Development: Patients with Infantile-onset Pompe disease should have a cross-reactive immunologic material (CRIM) assessment early in their disease course and be managed by a specialist knowledgeable in immune tolerance induction in Pompe disease to optimize treatment. Evidence suggests that patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy.

Please see Important Safety Information on pages 3-4 and [Full Prescribing Information](#) for complete details, including Boxed WARNING.

SAMPLE REIMBURSEMENT FORMS

These sample claim forms are intended for reference only. Reimbursement codes are subject to continual change. Please confirm the accuracy of the codes used with each payer.

Annotated claim form CMS-1500¹²

For claims submitted by noninstitutional healthcare providers¹³

- A** **Field 21:** Enter the appropriate ICD-10-CM diagnosis code
- B** **Field 24A:** Enter the date of service for each procedure. Include the NDC information, if required, in the shaded area above each date
- C** **Field 24B:** Enter the appropriate Place of Service code (office, infusion center, etc)
- D** **Field 24D:** Include any payer-required details, such as HCPCS (J code), CPT codes, and modifiers
- E** **Field 24E:** Enter the diagnosis code reference letter or number from Field 21 that relates to the date of service and the services or procedures performed

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

Field A: Points to Field 21 (Diagnosis Code) in the shaded area.

Field B: Points to Field 24A (Date of Service) in the shaded area.

Field C: Points to Field 24B (Place of Service) in the shaded area.

Field D: Points to Field 24D (HCPCS/CPT codes) in the shaded area.

Field E: Points to Field 24E (Diagnosis Code Reference) in the shaded area.

Please see Important Safety Information on pages 3-4 and Full Prescribing Information for complete details, including Boxed WARNING.

Annotated claim form CMS-1450¹⁴

For claims submitted by hospitals, nursing facilities, and other institutional inpatient and outpatient providers¹⁵

A **Field 42:** Enter the 4-digit revenue code that best describes the service provided, in accordance with the hospital billing policy

B **Field 43:** Enter the corresponding description of service (eg, IV therapy)

C **Field 44:** Include any payer-required details, such as relevant HCPCS and CPT codes

D **Field 66:** Enter the appropriate ICD-10-CM diagnosis codes

E **Field 80:** Provide any required detailed information, such as the drug name, total dosage and strength, method of administration, and 11-digit NDC (attach separately if needed)

The image shows a CMS-1450 claim form with several callouts:

- Callout A:** Points to Field 42 (Revenue Code) in the 4300-4399 section.
- Callout B:** Points to Field 43 (Description) in the 4300-4399 section.
- Callout C:** Points to Field 44 (HCPCS/CPT Codes) in the 4300-4399 section.
- Callout D:** Points to Field 66 (ICD-10-CM Diagnosis Codes) in the 6700-6799 section.
- Callout E:** Points to Field 80 (Remarks) in the 8000-8099 section.

ADDITIONAL BILLING AND CODING CONSIDERATIONS

Reimbursement considerations

Lumizyme is designed to be prepared and administered by a healthcare provider, in both outpatient and home settings. Lumizyme may be eligible for reimbursement by commercial payers and Medicare.¹⁶ Please refer to the individual patient's plan to determine any applicable coverage requirements. The specifics of coverage may vary by payer.

When filing a claim

Because there is more than one enzyme replacement therapy (ERT) available to treat late-onset Pompe disease (LOPD), Lumizyme coverage should be confirmed with payers prior to administration in patients who have been diagnosed with LOPD.

Some payers have policies that may affect coverage for Lumizyme. These include:

- **Site of care:** Some payers may have coverage rules that restrict where patients can receive certain types of medical care, such as infusions
- **Network providers:** Some payers have exclusive contracts with in-network or participating providers to administer infusion therapies; these may include contracts for coverage in physician offices and outpatient settings or with specialty pharmacies that provide drugs and biologics to the provider
- **Prior authorization:** Many plans may require providers to obtain prior authorization (eg, statement of medical necessity) to begin a course of treatment; check with the payer to determine their process, requirements, and method for requesting authorization

Documenting medical necessity

Lumizyme is a medication used to treat a rare disease. Therefore, some insurers may not be familiar with Lumizyme and may require additional documentation to process a prior authorization or a claim upon receipt. Documentation requirements might include:

- Statement of medical necessity from the attending physician (see next page)
- Lumizyme Prescribing Information
- Details on the patient's case history, previous therapy, and clinical course

IMPORTANT SAFETY INFORMATION (cont'd)

Monitoring: Laboratory Tests: Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter. Patients who experience hypersensitivity reactions, including anaphylaxis, may also be tested for IgE antibodies to LUMIZYME and other mediators of anaphylaxis.

Sample Statement of Medical Necessity

STATEMENT OF MEDICAL NECESSITY FOR THE TREATMENT OF POMPE DISEASE																	
Patient Information	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Patient Name:</td> <td colspan="3">Address:</td> </tr> <tr> <td>Date of Birth:</td> <td>City:</td> <td>State:</td> <td>ZIP:</td> </tr> <tr> <td>Gender: <input type="radio"/> Male <input type="radio"/> Female</td> <td>Phone No. (Home):</td> <td colspan="2"></td> </tr> <tr> <td></td> <td>Phone No. (Work):</td> <td colspan="2"></td> </tr> </table>	Patient Name:	Address:			Date of Birth:	City:	State:	ZIP:	Gender: <input type="radio"/> Male <input type="radio"/> Female	Phone No. (Home):				Phone No. (Work):		
Patient Name:	Address:																
Date of Birth:	City:	State:	ZIP:														
Gender: <input type="radio"/> Male <input type="radio"/> Female	Phone No. (Home):																
	Phone No. (Work):																
Insurance Information	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Insurance Co.:</td> <td>Policy Holder Name:</td> </tr> <tr> <td>Subscriber ID No.:</td> <td>Insurance Phone No.:</td> </tr> <tr> <td>Group No.:</td> <td></td> </tr> </table>	Insurance Co.:	Policy Holder Name:	Subscriber ID No.:	Insurance Phone No.:	Group No.:											
Insurance Co.:	Policy Holder Name:																
Subscriber ID No.:	Insurance Phone No.:																
Group No.:																	
Medical Assessment	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Patient Weight: _____ (kg/lb)</td> <td>Patient Height: _____ (cm/in)</td> </tr> <tr> <td>Respiratory: _____</td> <td>Musculoskeletal: _____</td> </tr> <tr> <td>Cardiac: _____</td> <td>Other: _____</td> </tr> </table> <p>Enclosures <include patient medical history, full Prescribing Information, additional supporting clinical documents> *Attach copy of GAA enzyme assay or GAA gene sequencing</p>	Patient Weight: _____ (kg/lb)	Patient Height: _____ (cm/in)	Respiratory: _____	Musculoskeletal: _____	Cardiac: _____	Other: _____										
Patient Weight: _____ (kg/lb)	Patient Height: _____ (cm/in)																
Respiratory: _____	Musculoskeletal: _____																
Cardiac: _____	Other: _____																
Diagnosis	<p>Pompe Disease E74.02: Date of Confirmed Diagnosis: _____</p> <p>Please indicate Pompe disease subtype (if known): <input type="radio"/> Infantile-onset Pompe disease (IOPD) <input type="radio"/> Late-onset Pompe disease (LOPD)</p> <p>How was the diagnosis confirmed? Confirmation REQUIRES the presence of #1 OR #2 below.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> <p><input type="checkbox"/> GAA Enzyme Activity (must be reduced or absent):</p> <p>1. Value: _____ (units) Date: _____</p> <p>Normal Reference Range: _____ (for laboratory & sample) _____</p> <p><input type="checkbox"/> GAA Gene Sequencing:</p> <p>Date: _____</p> <p>List DNA sequence changes:</p> <p>1. _____</p> <p>2. _____</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Sample Type:</p> <p><input type="checkbox"/> Blood <input type="radio"/> Purified Lymphocytes <input type="radio"/> Mixed Leukocytes</p> <p><input type="checkbox"/> Muscle Tissue <input type="checkbox"/> Cultured Skin Fibroblasts</p> <p>Additional Information (if needed):</p> </td> </tr> </table>	<p><input type="checkbox"/> GAA Enzyme Activity (must be reduced or absent):</p> <p>1. Value: _____ (units) Date: _____</p> <p>Normal Reference Range: _____ (for laboratory & sample) _____</p> <p><input type="checkbox"/> GAA Gene Sequencing:</p> <p>Date: _____</p> <p>List DNA sequence changes:</p> <p>1. _____</p> <p>2. _____</p>	<p>Sample Type:</p> <p><input type="checkbox"/> Blood <input type="radio"/> Purified Lymphocytes <input type="radio"/> Mixed Leukocytes</p> <p><input type="checkbox"/> Muscle Tissue <input type="checkbox"/> Cultured Skin Fibroblasts</p> <p>Additional Information (if needed):</p>														
<p><input type="checkbox"/> GAA Enzyme Activity (must be reduced or absent):</p> <p>1. Value: _____ (units) Date: _____</p> <p>Normal Reference Range: _____ (for laboratory & sample) _____</p> <p><input type="checkbox"/> GAA Gene Sequencing:</p> <p>Date: _____</p> <p>List DNA sequence changes:</p> <p>1. _____</p> <p>2. _____</p>	<p>Sample Type:</p> <p><input type="checkbox"/> Blood <input type="radio"/> Purified Lymphocytes <input type="radio"/> Mixed Leukocytes</p> <p><input type="checkbox"/> Muscle Tissue <input type="checkbox"/> Cultured Skin Fibroblasts</p> <p>Additional Information (if needed):</p>																
Treatment Recommendation	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Lumizyme® (alglucosidase alfa)</td> <td>NDC #: 58468-0160-1 (carton of 1 single-use vial) NDC #: 58468-0160-2 (carton of 10 single-use vials)</td> </tr> <tr> <td>Dose: _____ mg/kg</td> <td>Frequency: _____</td> </tr> <tr> <td>Therapy Start Date: _____</td> <td></td> </tr> </table>	Lumizyme® (alglucosidase alfa)	NDC #: 58468-0160-1 (carton of 1 single-use vial) NDC #: 58468-0160-2 (carton of 10 single-use vials)	Dose: _____ mg/kg	Frequency: _____	Therapy Start Date: _____											
Lumizyme® (alglucosidase alfa)	NDC #: 58468-0160-1 (carton of 1 single-use vial) NDC #: 58468-0160-2 (carton of 10 single-use vials)																
Dose: _____ mg/kg	Frequency: _____																
Therapy Start Date: _____																	
Physician Authorization	<p>I certify that the above-indicated therapy is medically necessary, and the information provided is accurate to the best of my knowledge.</p> <p>Physician Name (printed): _____ Date: _____</p> <p>Address: _____ City: _____ State: _____ ZIP: _____</p> <p>Phone No.: _____</p> <p>Physician Signature: _____</p> <p>Physician's Medical License No.: _____ State Issued: _____</p>																
<p><small>©2024 Sanofi. All rights reserved. Lumizyme and Sanofi are registered trademarks of Sanofi or its affiliates. MAT-US-2014359-v3.0-06/2024</small></p>																	

Note that some payers have their own specific form for medical necessity, which should be used in those cases.

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS

The most frequently reported adverse reactions (≥5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.

Please see Important Safety Information on pages 3-4 and Full Prescribing Information for complete details, including Boxed WARNING.



DOSING AND STORAGE INFORMATION³

Dosing

Lumizyme is for intravenous infusion only. The recommended dosage for patients with LOPD or IOPD is 20 mg/kg body weight administered every 2 weeks. The total volume of infusion is determined by the patient's body weight and should be administered over approximately 4 hours. Prior to Lumizyme administration, pretreating with antihistamines, antipyretics, and/or corticosteroids should be considered.

Lumizyme should be administered with an infusion pump at an initial rate of no more than 1 mg/kg/hr. The infusion rate may be increased in a stepwise manner, after patient tolerance to each infusion rate is established, by 2 mg/kg/hr every 30 minutes, until a maximum rate of 7 mg/kg/hr is reached.

The infusion rate may be slowed or temporarily stopped in the event of mild-to-moderate hypersensitivity reactions. In the event of anaphylaxis or severe hypersensitivity reaction, administration of Lumizyme should be discontinued and appropriate medical treatment should be initiated.

Please see the full Prescribing Information for complete details regarding infusion rates, as well as additional details regarding preparation and administration.

Storage

Lumizyme should be stored under refrigeration between 2°C and 8°C (36°F and 46°F). Once reconstituted and diluted, Lumizyme should be administered without delay. If immediate use is not possible, the reconstituted and diluted solution is stable for up to 24 hours when stored at 2°C to 8°C (36°F to 46°F). The reconstituted and diluted alglucosidase alfa solution should be protected from light. Storage of the solution at room temperature is not recommended.

Do not use Lumizyme after the expiration date on the vial.

IMPORTANT SAFETY INFORMATION (cont'd)

Infusion Associated Reactions (IARs): Infusion Associated Reactions (IARs) have been observed in patients treated with Lumizyme. Discontinue immediately or adjust the infusion rate and provide medical treatment based on the severity of the reaction. Closely monitor patients who have experienced IARs when re-administering LUMIZYME.

PATIENT SUPPORT SERVICES



CareConnectPSS®

CareConnectPSS, personalized support services for patients, represents Sanofi’s more than 35-year commitment to supporting the rare disease community. CareConnectPSS is designed to support each patient’s unique journey.

Our range of support to help patients manage living with a rare disease

- Programs and other offerings on a range of disease, treatment, and support topics
- Dedicated CareConnectPSS Case Managers and Patient Education Liaisons
- Disease-specific information, including genetic education and other resources
- Care coordination for moves, vacations, and more
- Assistance with understanding new or changing insurance, as well as resources to help with out-of-pocket costs

Access to these and other services is voluntary, and your patients are not obligated to begin treatment if they contact us. You and your patients make all treatment-related decisions, and most importantly the privacy and security of their personal information are always protected.

CareConnectPSS Co-Pay Program

Helps eligible patients in the United States who are prescribed Lumizyme pay for eligible out-of-pocket drug costs and specified infusion-related charges, including co-pays, coinsurance, and deductibles, up to the program maximum.*

CareConnectPSS Patient Assistance Program

Provides Lumizyme at no cost to eligible patients who do not have health insurance or cannot access Lumizyme under the terms of their insurance plan(s), until insurance coverage for Lumizyme is secured.†

To learn more, contact a Case Manager at
1-800-745-4447 (Option 3)
 or visit www.CareConnectPSS.com

*Patients must be eligible under applicable state law(s). Patients whose medication or infusion-related costs are covered by a state or federal health care program, including but not limited to Medicare, Medicare Part D, Medigap, Medicaid, Veterans Affairs (VA), Department of Defense (DoD), or TRICARE®, are not eligible. Patient must live in the US or a US territory. Other terms and conditions of the Program apply.

Co-Pay Program does not cover or provide support for MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, pre-medications/other medications, transportation or other related services associated with treatment. In accordance with state law, infusion-related costs are not covered for commercially insured patients residing in MA or RI. Sanofi reserves the right to modify or discontinue the program at any time without notice. Savings may vary depending on patients’ out-of-pocket costs.

†Patient Assistance Program eligibility criteria include the following:

- Patient must not have insurance coverage or not have access to Lumizyme under the terms of the patient’s insurance plan(s)
- Patient must live in the US or a US territory
- Patient must have a valid prescription from a health care provider licensed in the US or a US territory
- Other terms and conditions of the Program apply

TRICARE is a registered trademark of the Department of Defense, Defense Health Agency.

Please see Important Safety Information on pages 3-4 and Full Prescribing Information for complete details, including Boxed WARNING.



ORDERING INFORMATION FOR LUMIZYME

To order Lumizyme, contact one of the authorized distributors listed below:

SPECIALTY DISTRIBUTOR	Phone	Web
Cardinal Health	800-926-3161	cardinalhealth.com
Cardinal Health Specialty Pharmaceutical Distribution	800-768-2002	cardinalhealth.com/en/solutions/specialty-distribution-services.html
McKesson Plasma and Biologics	877-625-2566	connect.mckesson.com
McKesson Pharmaceutical Distribution	855-625-4677	mckesson.com
McKesson Specialty Health	800-482-6700	mcs.mckesson.com
Morris & Dickson Specialty Distribution	800-388-3833	mdspecialtydist.com

To order Lumizyme directly from Sanofi:

DIRECT ORDER CONTACT	Phone	Email
Rare Disease Product Services	800-745-4447, Option 1	CO@Sanofi.com

Lumizyme is also available through most specialty pharmacies.

IMPORTANT SAFETY INFORMATION (cont'd)

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for LUMIZYME infusion.

Please see Important Safety Information on pages 3-4 and Full Prescribing Information for complete details, including Boxed WARNING.



Lumizyme[®]
(alglucosidase alfa)

REFERENCES

1. Techtargt. ICD-10-CM (clinical modification). Updated June 2024. Accessed June 4, 2024. <https://www.techtargt.com/searchhealthit/definition/ICD-10-CM>
2. Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. Accessed June 4, 2024. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf
3. Lumizyme. Prescribing information. Sanofi.
4. Drugs.com. National drug codes explained. Updated November 1, 2023. Accessed June 4, 2024. <https://www.drugs.com/ndc.html>
5. Maryland Department of Health. National Drug Code (NDC) conversion table. Accessed June 4, 2024. <https://health.maryland.gov/phpa/OIDEOR/IMMUN/Shared%20Documents/Handout%203%20-%20NDC%20conversion%20to%2011%20digits.pdf>
6. American Medical Association. CPT® overview and code approval. Accessed June 4, 2024. <https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval>
7. Synovec MS, Brin KP, Jagmin CL, et al, eds. CPT® 2020 Professional Edition. American Medical Association; 2019:730-735.
8. American Academy of Professional Coders. What is HCPCS? Reviewed March 25, 2024. Accessed June 4, 2024. <https://www.aapc.com/resources/medical-coding/hcpcs.aspx>
9. HCPCS.codes. HCPCS Code J0221. Accessed June 4, 2024. <https://hcpcs.codes/j-codes/J0221/>
10. Centers for Medicare & Medicaid Services. Billing and Coding: JW Modifier Billing Guidelines (A55932). Revised March 21, 2024. Accessed June 4, 2024. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleID=55932&msclkid=96c2ce72c70111ec8f3eea67c200eeda>
11. Centers for Medicare & Medicaid Services. Place of Service Codes for Professional Claims. Updated May 2, 2024. Accessed June 4, 2024. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Downloads/Website-POS-database.pdf>
12. Centers for Medicare & Medicaid Services. Sample form CMS-1500. Accessed June 4, 2024. <https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/Downloads/CMS1500.pdf>
13. Centers for Medicare & Medicaid Services. Professional paper claim form (CMS-1500). Accessed June 4, 2024. <https://www.cms.gov/Medicare/Billing/ElectronicBillingEDITrans/1500>
14. Centers for Medicare & Medicaid Services. CMS-1450. Accessed June 4, 2024. <https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing-Items/CMS-1450>
15. Centers for Medicare & Medicaid Services. Medicare Billing: Form CMS-1450 and the 837 Institutional. Accessed June 4, 2024. <https://www.cms.gov/files/document/837i-form-cms-1450-mln006926.pdf>
16. Medicare.gov. Prescription drug (outpatient). Accessed June 4, 2024. <https://www.medicare.gov/coverage/prescription-drugs-outpatient>



©2024 Sanofi. All rights reserved.

Lumizyme, CareConnectPSS, and Sanofi are registered trademarks of Sanofi or an affiliate.

All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi.

MAT-US-2002147-v4.0-06/2024

Please see Important Safety Information on pages 3-4 and Full Prescribing Information for complete details, including Boxed WARNING.



Lumizyme®
(alglucosidase alfa)